The carcinogen was not detected in the permeable pump-controlled release agent-type hydrochloric acid metformin nida.

"God's medicine" carcinogenic? Chinese drugs have not detected carcinogens In March this year, independent testing laboratory Valisure in the United States 22 companies selling metformin, a total of 38 batches of product test results showed that 11 companies of 16 batches of metformin preparations in the NDMA exceeded the standard, some preparations even exceeded the standard of nearly 10 times.followed by a new round of testing by the FDA.it is worth noting that the two test results of Chinese pharmaceutical companies did not detect NDMA products., by Baiyang Pharmaceuticals production of metformin control release agent Nida, is the united States market is the only three batches of the detection of NDMA did not detect the Chinese brand, the drug is the use of permeable pump control release technology once a day of the new metformin, has been listed in the United States and China simultaneously marketed.the origin of carcinogens is doubtful, multi-system source control is vital NDMA why it is present in metformin preparations, and seriously exceeded the standard? Lei Jifeng, director of Baiyang Pharmaceuticals and former chairman of the International Pharmaceutical Engineering Association (ISPE) in China, said, "The existing test results cannot specify the source of the genetically toxic substance, and it is currently speculated that the NDMA exceeds the standard may be due to the prescription process of metformin apiandic drugs and preparations, the formation of genetically toxic impurities and api synthesis steps, solvents, preparation methods and so on."" Naida had been thoroughly tested before entering the market.Baiyang Pharmaceuticals on the quality of metformin control release agent formed a systematic and comprehensive control strategy, including the use of standardized and safe API and accessories, strict production process control and strict testing, the current test results can prove that Baiyang Pharmaceuticals in all aspects of the pharmaceutical have maintained a high level of safety norms.the FDA strictly check the ndMA content of metformin in the operation of the standard, for strictly adhere to the safety bottom line of the Chinese pharmaceutical enterprises or will be "dangerous" in the "machine" - the pharmaceutical companies strictly control the production links, the production of the drug itself quality, safety, will be able to replace the genetic toxic impurities exceeded the standard of the same drugs.take Baiyang Pharmaceuticals as an example, metformin-controlled release agent will benefit more diabetics in the U.S. and China markets in the future, ushering in new opportunities for expansion..